Equities Analysts Offer Predictions for TMO Q1 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Thursday, January 30th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $5.10 per share for the quarter, down from their previous estimate of $5.43. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.29 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q1 2026 earnings at $5.67 EPS, Q2 2026 earnings at $6.28 EPS, Q3 2026 earnings at $6.33 EPS and Q4 2026 earnings at $7.45 EPS.

TMO has been the topic of a number of other reports. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday. Raymond James restated an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Citigroup boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a report on Friday, January 31st. Finally, Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $580.63 on Monday. Thermo Fisher Scientific has a 12-month low of $493.30 and a 12-month high of $627.88. The firm has a market capitalization of $222.09 billion, a PE ratio of 35.13, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77. The firm has a 50-day moving average price of $542.95 and a 200 day moving average price of $571.55. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.44%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 9,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds have recently bought and sold shares of the stock. Legacy Investment Solutions LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $26,000. Peterson Financial Group Inc. bought a new position in Thermo Fisher Scientific during the third quarter worth about $27,000. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. Finally, Missouri Trust & Investment Co bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.